Markets

MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial

Oct 23, 2026 · 09:24 AM ET· updated 1h ago

Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN

Why It Matters

MacroGenics tested a new cancer medicine on sick patients. Early results showed the medicine helped some patients, which is encouraging for the company's next steps.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MGNX2.43

-1.21 (-33.20%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.